Gastrointestinal Symptoms in Healthy Subjects and Patients With Irritable Bowel Syndrome
Assessment of Gastrointestinal Symptoms and Health-related Quality of Life in Healthy People and Patients With Irritable Bowel Syndrome
1 other identifier
observational
200
1 country
2
Brief Summary
The aim of this study performed in Irritable Bowel Syndrome (IBS) subjects and healthy patients is to demonstrate the ability of composite score of frequency of gastrointestinal symptoms to discriminate healthy subjects and IBS patients. The properties of this questionnaire of composite score of gastrointestinal symptoms frequency will be compared to other validated questionnaires (severity of IBS symptoms and HRQoL).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2011
Shorter than P25 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2011
CompletedFirst Submitted
Initial submission to the registry
October 19, 2011
CompletedFirst Posted
Study publicly available on registry
October 24, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2011
CompletedSeptember 20, 2016
September 1, 2016
1 month
October 19, 2011
September 19, 2016
Conditions
Keywords
Study Arms (2)
Healthy volunteers
100 healthy volunteers
IBS Subjects
100 IBS Subjects
Eligibility Criteria
Adult healthy subjects and adult IBS patients (Rome III criteria, all subtype)
You may qualify if:
- for Healthy subjects :
- Healthy women and men free-living subject aged from 18 to 65 years.
- Subject with a body mass index between 18 and 30, bounds included.
- Subject having given written consent to take part in the study.
- Chronic medical treatment-free excluding contraceptive and stable Hormonal Replacement Therapy
- for IBS Patients :
- IBS women and men free-living subject aged from 18 to 65 years
- Subject with a diagnosis of IBS according to Rome III criteria: recurrent abdominal pain or discomfort at least 3 days per month in the last 3 months associated with 2 or more of the following: improvement with defecation; onset associated with a change in frequency of stool; onset associated with a change in form (appearance) of stool.
- Subject with a diagnosis of IBS according to Rome III criteria with symptom onset at least 6 months prior to diagnosis.
- Subject having an IBS-SSS score higher or equal to 75 corresponding to an active phase of IBS symptoms.
- Subject having given written consent to take part in the study.
You may not qualify if:
- for Healthy subjects :
- Subject who, in the past, has consulted a general practitioner or a gastroenterologist for (IBS) or any other functional bowel disease including constipation and diarrhoea.
- Subject with known organic disease, including an inflammatory bowel disease, a benign or malign tumour of intestine or colon and significant systemic disease
- Subject treated with any chronic medical treatment that, in the investigator's opinion could interfere with the GI tract.
- Subject who underwent general anaesthesia in the preceding 4 weeks.
- Pregnant subject or breast-feeding subject at the time of the study.
- Subject with known immunosuppression
- Subject with any known food allergy
- Subject in a situation, which in the investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the subject.
- Subject not able to read, to understand and/or to answer to the questionnaires.
- for IBS Patients :
- If a subject fulfils with one of the following criteria, he/she must be excluded from the study:
- Subject with a diagnosis of IBS with clinical signs of alarm (rectorragy, fever, associated inflammatory articular signs, recent weight loss).
- Subject with known organic disease, including an inflammatory bowel disease, a benign or malign tumour of intestine or colon and significant systemic disease.
- Subject who underwent general anaesthesia in the preceding 4 weeks.
- +3 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Eurofins Optimed
Gières, 38610, France
Biofortis
Nantes, 44200, France
Related Publications (1)
Azpiroz F, Guyonnet D, Donazzolo Y, Gendre D, Tanguy J, Guarner F. Digestive Symptoms in Healthy People and Subjects With Irritable Bowel Syndrome: Validation of Symptom Frequency Questionnaire. J Clin Gastroenterol. 2015 Aug;49(7):e64-70. doi: 10.1097/MCG.0000000000000178.
PMID: 25014236DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 19, 2011
First Posted
October 24, 2011
Study Start
September 1, 2011
Primary Completion
October 1, 2011
Study Completion
November 1, 2011
Last Updated
September 20, 2016
Record last verified: 2016-09